Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study evaluating lipoprotein profile resulting from NGM282and effect of rosuvastatin on these changes in biopsy confirmed non alcoholic steatohepatitis patients.

Trial Profile

A study evaluating lipoprotein profile resulting from NGM282and effect of rosuvastatin on these changes in biopsy confirmed non alcoholic steatohepatitis patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs NGM 282 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Nov 2018 According to a NGM Biopharmaceuticals media release, data from the 3 mg biopsy cohort were presented at The International Liver Congress in Paris in April 2018.
    • 06 Nov 2018 According to a NGM Biopharmaceuticals media release, new data from the 1 mg biopsy cohort from this trial will be presented at The Liver Meeting of The American Association for the Study of Liver Diseases.
    • 16 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top